Abstract
It was 11 March 2020 when the World Health Organization (WHO) declared the name COVID-19 for coronavirus disease and also described it as a pandemic. Till that day 118,000 cases were confirmed of pneumonia with breathing problem throughout the world. At the start of New Year when COVID-19 came into knowledge a few days later, the gene sequencing of the virus was revealed. Today the number of confirmed cases is scary, i.e. 9,472,473 in the whole world and 484,236 deaths have been recorded by WHO till 26 June 2020. WHO's global risk assessment is very high [1]. The report is enlightening the lessons learned by India from the highly affected countries.
Keywords: Death rate, different scenario, fight against COVID-19, remedial action, WHO, risk assessment.
Current Signal Transduction Therapy
Title:How India Fights with COVID-19 Learning from Highly Affected Countries
Volume: 16 Issue: 3
Author(s): Pooja Sharma and Karan Veer*
Affiliation:
- Department of Instrumentation & Control Engineering, Dr. B.R. Ambedkar National Institute of Technology, Jalandhar 144011,India
Keywords: Death rate, different scenario, fight against COVID-19, remedial action, WHO, risk assessment.
Abstract: It was 11 March 2020 when the World Health Organization (WHO) declared the name COVID-19 for coronavirus disease and also described it as a pandemic. Till that day 118,000 cases were confirmed of pneumonia with breathing problem throughout the world. At the start of New Year when COVID-19 came into knowledge a few days later, the gene sequencing of the virus was revealed. Today the number of confirmed cases is scary, i.e. 9,472,473 in the whole world and 484,236 deaths have been recorded by WHO till 26 June 2020. WHO's global risk assessment is very high [1]. The report is enlightening the lessons learned by India from the highly affected countries.
Export Options
About this article
Cite this article as:
Sharma Pooja and Veer Karan *, How India Fights with COVID-19 Learning from Highly Affected Countries, Current Signal Transduction Therapy 2021; 16 (3) . https://dx.doi.org/10.2174/1574362415999200807154418
DOI https://dx.doi.org/10.2174/1574362415999200807154418 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Drug Options for Treatment of COVID-19: A Review
Coronaviruses Antiviral Activity of Substituted Salicylanilides - A Review
Mini-Reviews in Medicinal Chemistry Remdesivir, A Potential Drug for COVID-19 Treatment: A New Hope
Coronaviruses Modifications of Medical Care of Chronic Liver Diseases During COVID-19 Pandemic: Necessity or Novelty?
Infectious Disorders - Drug Targets Novel Coronavirus Disease and the Current Scenario of the Global Health Emergency
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Prevalence of COVID-19-like Symptoms among People Living with HIV, and Using Antiretroviral Therapy for Prevention and Treatment
Current HIV Research COVID-19: Morphology, Characteristics, Symptoms, Prevention, Clinical Diagnosis and Current Scenario
Coronaviruses Contactless Core-temperature Monitoring by Infrared Thermal Sensor using Mean Absolute Error Analysis
Recent Patents on Engineering Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight
Current Pharmaceutical Biotechnology COVID-19: An Update on Clinical Trials
Current Topics in Medicinal Chemistry Molecular Cloning, Sequence and Structural Analysis of Dehairing Mn2+ Dependent Alkaline Serine Protease (MASPT) of Bacillus pumilus TMS55
Protein & Peptide Letters Potential Inhibition of COVID-19 RNA-dependent RNA Polymerase by Hepatitis C Virus Non-nucleoside Inhibitors: An <i>In-silico</i> Perspective
Letters in Drug Design & Discovery Intercorrelation of Major DNA/RNA Sequence Descriptors - A Preliminary Study
Current Computer-Aided Drug Design Why Do We Still Lack a COVID-19 Vaccine? Searching for the Missing Pieces
Endocrine, Metabolic & Immune Disorders - Drug Targets A Pharmacophore Model Specific to Active Site of CYP1A2 with a Novel Molecular Modeling Explorer and CoMFA
Medicinal Chemistry Potential Immunotherapy against SARS-CoV-2: Strategy and Status
Coronaviruses Recent Patents on Cell Cycle Regulatory Proteins
Recent Patents on Biotechnology Thiazole Compounds as Antiviral Agents: An Update
Medicinal Chemistry Circadian Clock Genes: Targeting Innate Immunity for Antiviral Strategies Against COVID-19
Current Neurovascular Research COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail
Infectious Disorders - Drug Targets